The blockade of NRP1-VEGFR2 interaction led to restriction of tumor growth and angiogenesis in a mouse model of CRC [55], while targeting NRP1 with a specific antagonist prevented migration induction in CRC cells adapted to the treatment with the VEGFR-targeting drug sunitinib [54]. This evidence concerns the gene NRP1 and neoplasm.